Schwarze, Svea
Schaadt, Nadine S.
Sobotta, Viktor M. G.
Spicher, Nicolai
Skripuletz, Thomas
Esmaeilzadeh, Majid
Krauss, Joachim K.
Hartmann, Christian
Deserno, Thomas M.
Feuerhake, Friedrich
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (2020_EKPK.20)
Bundesministerium für Bildung und Forschung (FKZ 31L0237A)
Medizinische Hochschule Hannover (MHH)
Article History
Received: 6 September 2023
Accepted: 12 January 2024
First Online: 23 January 2024
Competing interests
: Christian Hartmann receives license fees from the company Dianova due to a patent on the antibody H09 against mutated IDH1 R132H protein used in the study. Thomas Skripuletz reports honoraria for lectures and travel expenses for attending meetings from Alexion, Alnylam Pharmaceuticals, argenx, Bayer Vital, Biogen, Celgene, Centogene, CSL Behring, Euroimmun, Janssen-Cilag, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Siemens, Swedish Orphan Biovitrum, Teva, Viatris. All other authors declare that they have no competing interests.